Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2014; 20(42): 15564-15579
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15564
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15564
Gene product | Target drug | Mechanism | Ref. |
hENT1 | Gemcitabine | Nucleoside inhibitor, prevents DNA synthesis in cancer cells | [59-64] |
TS/DPD | 5-FU/S-1 | Suicide inhibitor of TS, prevents DNA synthesis in cancer cells | [65-71] |
EGFR | Erlotinib | Tyrosine kinase inhibitor, prevents EGFR-mediated cell cycle progression and cellular proliferation | [72-79] |
CA 19-9 | N/A | N/A | [80-88] |
SPARC | Nab-paclitaxel | Disruption of microtubule formation during mitosis | [12,89-94] |
SMAD4 | N/A | Tumor suppression, initiation, and metastasis | [95-99] |
- Citation: Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World J Gastroenterol 2014; 20(42): 15564-15579
- URL: https://www.wjgnet.com/1007-9327/full/v20/i42/15564.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i42.15564